Phreesia, Inc. (NYSE:PHR) Q2 2025 Earnings Conference Call September 4, 2024 5:00 PM ET Company Participants Balaji Gandhi - Chief Financial Officer Chaim Indig - Chief Executive Officer Conference Call Participants Anne Samuel - JPMorgan Ryan Daniels - William Blair Scott Schoenhaus - KeyBanc Jessica Tassan - Piper Sandler Jailendra Singh - Truist Securities Glen Santangelo - Jefferies Stephanie Davis - Barclays Joe Vruwink - Baird John Ransom - Raymond James Richard Close - Canaccord Security Daniel Gross ...

Phreesia (PHR) reported $102.12 million in revenue for the quarter ended July 2024, representing a year-overyear increase of 19%. EPS of -$0.31 for the same period compares to -$0.68 a year ago. The reported revenue represents a surprise of +0.35% over the Zacks Consensus Estimate of $101.76 million. With the consensus EPS estimate being -$0.37, the EPS surprise was +16.22%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Stree ...

Investor Presentation Second quarter | Fiscal year 2025 Phreesia Disclaimer This presentation includes express or implied statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or our future financial or operating performance and may contain projections of our future results of operat ...

Phreesia (PHR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.68 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 16.22%. A quarter ago, it was expected that this developer of health care software would post a loss of $0.51 per share when it actually produced a loss of $0.35, delivering a surprise of 31.37%. Over the last four quarters, the ...

Revenue Performance - Total revenue for Q2 fiscal 2025 was $102.1 million, up 19% year-over-year[1] - Revenue outlook for fiscal 2025 is maintained at $416 million to $426 million, implying 17% to 20% year-over-year growth[2] - Total revenues for the six months ended July 31, 2024, increased to $203.33 million, up from $169.68 million in the same period in 2023[12] - Subscription and related services revenue for the six months ended July 31, 2024, grew to $95.35 million, up from $77.19 million in the same period in 2023[12] - Payment processing fees revenue for the six months ended July 31, 2024, increased to $52.36 million, compared to $47.88 million in the same period in 2023[12] - Network solutions revenue for the six months ended July 31, 2024, rose to $55.62 million, up from $44.60 million in the same period in 2023[12] Healthcare Services Clients (AHSCs) - Average number of healthcare services clients (AHSCs) reached 4,169, up 21% year-over-year[1] - AHSCs expected to reach approximately 4,200 in fiscal 2025 and 4,500 in fiscal 2026[2] - Average number of healthcare services clients (AHSCs) for the three months ended July 31, 2024 was 4,169, compared to 3,445 in the same period in 2023[20] Profitability and Loss - Net loss improved to $18.0 million compared to $36.8 million in the prior year[1] - Net loss for the six months ended July 31, 2024, was $37.73 million, compared to $74.30 million in the same period in 2023[12] - Net loss for Q3 2024 was $18.0 million, a 51% improvement compared to $36.8 million in Q3 2023[17] - Comprehensive loss for the six months ended July 31, 2024, was $37.74 million, compared to $74.30 million in the same period in 2023[13] Adjusted EBITDA - Adjusted EBITDA was $6.5 million, compared to negative $11.5 million in the prior year[1] - Adjusted EBITDA outlook for fiscal 2025 updated to $26 million to $31 million[2] - Adjusted EBITDA for Q3 2024 was $6.5 million, a significant improvement from $(11.5) million in Q3 2023[17] Cash Flow and Liquidity - Free cash flow turned positive at $3.7 million, compared to negative $15.2 million in the prior year[1] - Cash and cash equivalents as of July 31, 2024, were $81.8 million[1] - Net cash provided by operating activities in Q3 2024 was $11.1 million, compared to $(9.3) million in Q3 2023[14] - Cash and cash equivalents as of July 31, 2024, were $81.80 million, compared to $87.52 million as of January 31, 2024[11] - Free cash flow for the three months ended July 31, 2024 was $3.658 million, compared to $(15.174) million in the same period in 2023[18] - Free cash flow for the six months ended July 31, 2024 was $(2.509) million, compared to $(34.912) million in the same period in 2023[18] Operating Expenses and Costs - Adjusted operating expenses for the three months ended July 31, 2024 were $78.918 million, compared to $81.504 million in the same period in 2023[19] - Adjusted operating expenses for the six months ended July 31, 2024 were $157.745 million, compared to $163.032 million in the same period in 2023[19] - Stock-based compensation expense for Q3 2024 was $16.4 million, a 12% decrease from $18.6 million in Q3 2023[14] - Depreciation and amortization expenses increased 8% to $7.3 million in Q3 2024 from $6.8 million in Q3 2023[14] - Capital expenditures for Q3 2024 totaled $7.4 million, a 24% decrease from $9.7 million in Q3 2023[14] - Interest expense for Q3 2024 was $0.4 million, a 29% increase from $0.3 million in Q3 2023[15] Balance Sheet and Assets - Total assets as of July 31, 2024, were $362.24 million, slightly down from $370.33 million as of January 31, 2024[11] - Accounts receivable, net as of July 31, 2024, were $61.27 million, down from $64.86 million as of January 31, 2024[11] - Total current liabilities as of July 31, 2024, were $102.00 million, compared to $110.12 million as of January 31, 2024[11] - Accounts receivable increased by $5.0 million in Q3 2024, compared to a decrease of $0.8 million in Q3 2023[14] - Deferred revenue decreased by $2.7 million in Q3 2024, compared to a decrease of $1.8 million in Q3 2023[14] Revenue per AHSC - Total revenue per AHSC expected to increase in fiscal 2025 compared to $98,944 in fiscal 2024[2] - Healthcare services revenue per AHSC for the three months ended July 31, 2024 was $17,729, compared to $18,268 in the same period in 2023[20] - Total revenue per AHSC for the three months ended July 31, 2024 was $24,494, compared to $24,914 in the same period in 2023[20] Payment Volume and Processing - Patient payment volume for the three months ended July 31, 2024 was $1.093 billion, compared to $989 million in the same period in 2023[23] - Payment facilitator volume percentage for the three months ended July 31, 2024 was 81%, compared to 82% in the same period in 2023[23]

Wall Street analysts expect Phreesia (PHR) to post quarterly loss of $0.37 per share in its upcoming report, which indicates a year-over-year increase of 45.6%. Revenues are expected to be $102.05 million, up 18.9% from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe. Prior to a company's earnings announcement, it is crucial to co ...

Shares of Phreesia (PHR) have gained 13.2% over the past four weeks to close the last trading session at $22.65, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $28.94 indicates a potential upside of 27.8%. While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because t ...

The change in a company's future earnings potential, as reflected in earnings estimate revisions, and the nearterm price movement of its stock are proven to be strongly correlated. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically bu ...

The investigation concerns whether Phreesia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On May 30, 2024, Phreesia issued a press release announcing financial results for the first quarter of its fiscal year 2025. Among other items, Phreesia update its "revenue outlook for fiscal year 2025 to a range of $416 million to $426 million from a previous range of $424 million to $434 million." Phreesia advised that "[t]he updated revenue range ...

The investigation concerns whether Phreesia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Phreesia, Inc. ("Phreesia" or the "Company") (NYSE: PHR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. [Click here for information about joining the class action] On May 30, 2024, Phr ...